Keywords: USA, FDA, Safety review, Prostate cancer drugs

US FDA reviewing safety of commonly-used prostate cancer drugs, citing possible diabetes and cardiac risks

Article | 05 May 2010

In the wake of approving the first prostate cancer vaccine - Dendreon’s Provenge (sipuleucel-T) - last week (The Pharma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in